Once-daily carbachol/brimonidine tartrate significantly improves aging-related vision loss ...

The FDA approved a fixed-dose combination of carbachol and brimonidine tartrate for presbyopia, offering a noninvasive alternative to glasses or surgery. Phase 3 trials demonstrated superior ...

Yuvezzi, a combination cholinergic agonist and alpha-adrenergic agonist, is now FDA-approved as a once-daily treatment for ...

The FDA approved Yuvezzi, an eye drop for the treatment of presbyopia, with broad U.S. availability expected in the second quarter, according to a press release from Tenpoint Therapeutics. Yuvezzi ...

Credit: Alcon. The active ingredient in Tryptyr is acoltremon, an agonist of transient receptor potential melastatin 8 thermoreceptors. Tryptyr significantly improved tear production compared with ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Phentolamine ophthalmic solution 0.75% will be evaluated ...

NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that VEVYE® (cyclosporine ophthalmic solution) 0.1%, a patented, non‑preserved, ...

(RTTNews) - Glenmark Pharmaceuticals Ltd. (GLENMARK.NS), Friday announced that it has introduced Latanoprost Ophthalmic Solution, 0.005 percent, a bioequivalent and therapeutically equivalent ...

BRIDGEWATER, N.J., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company ...

Ace Therapeutics announces its preclinical ophthalmic drug development services to help expedite the discovery of ...